Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Exchange Rate Effect (2016 - 2025)

KalVista Pharmaceuticals' Exchange Rate Effect history spans 8 years, with the latest figure at $3.4 million for Q2 2025.

  • For Q2 2025, Exchange Rate Effect rose 4645.95% year-over-year to $3.4 million; the TTM value through Apr 2025 reached $3.8 million, up 414.43%, while the annual FY2025 figure was $2.6 million, 317.56% up from the prior year.
  • Exchange Rate Effect for Q2 2025 was $3.4 million at KalVista Pharmaceuticals, up from $407000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $3.4 million in Q2 2025 and bottomed at -$621000.0 in Q1 2024.
  • The 3-year median for Exchange Rate Effect is $84000.0 (2023), against an average of $382142.9.
  • The largest annual shift saw Exchange Rate Effect skyrocketed 39.29% in 2024 before it soared 4645.95% in 2025.
  • A 3-year view of Exchange Rate Effect shows it stood at -$602000.0 in 2023, then soared by 167.61% to $407000.0 in 2024, then skyrocketed by 726.54% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Exchange Rate Effect are $3.4 million (Q2 2025), $407000.0 (Q4 2024), and $117000.0 (Q3 2024).